Cell therapy trial for moderate Alzheimer's disease
Part of Brain & nervous system clinical trials.
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 85 years old.
- You need a reliable caregiver (like a family member or friend) who can come to study visits and help with assessments.
- You must have a brain scan showing Alzheimer's disease (amyloid PET) done in the last 6 months.
- You should be at a moderate stage of Alzheimer's, with a certain score on a memory and thinking test.
- You cannot have had cancer (except minor skin cancer) in the last 5 years, or be on blood thinners, or have had a recent stroke or heart attack.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial continues treatment for people who finished the earlier SNK01-AD01 study. It tests a personalized cell therapy (SNK01) to see if ongoing treatment is safe and helpful for Alzheimer's disease.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This trial tests a new treatment called NMS-01 for people with mild to moderate Alzheimer's disease. It aims to see if it's safe and may help with symptoms.
This trial tests whether a supplement called Neuroaid II can help people with mild to moderate Alzheimer's disease. It is a pill taken alongside your usual Alzheimer's treatments, and the study aims to see if it can slow down memory decline.
Hear when a new Moderate Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.